{"schema_version":"secwatch.filing_event.v1","accession":"0001439222-25-000090","form_type":"8-K","ticker":"AGIO","cik":"0001439222","company_name":"AGIOS PHARMACEUTICALS, INC.","filed_at":"2025-08-04T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.000652+00:00","generated_at":"2026-05-17T21:24:25.122251+00:00","sec_items":["7.01"],"event_type":"regulatory","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Agios responds to analyst report on PYRUKYND safety data; Saudi Arabia approves PYRUKYND for thalassemia","bullets":["Analyst report on Aug 4, 2025 references four FAERS cases; Agios says benefit-risk profile unchanged.","Three cases reported to Agios: two for PK deficiency patients on commercial PYRUKYND, one expanded access for sickle cell.","Fourth case reported directly to FDA; Agios evaluating via pharmacovigilance processes.","Saudi FDA approved PYRUKYND for adult patients with alpha- or beta-thalassemia (both non-transfusion and transfusion dependent)."],"urls":{"canonical":"https://secwatch.observer/filing/0001439222-25-000090","json":"https://secwatch.observer/filing/0001439222-25-000090.json","markdown":"https://secwatch.observer/filing/0001439222-25-000090.md","text":"https://secwatch.observer/filing/0001439222-25-000090.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1439222/000143922225000090/0001439222-25-000090-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1439222/000143922225000090/agio-20250804.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T21:24:25.122251+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}